T. Rowe Price Associates
AH

T. Rowe Price Associates’s Accretive Health AH Stock Holding History

T. Rowe Price Associates’s Portfolio AH Stock Details AH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-540,000
Closed -$4.95M – 2548
2013
Q4 		$4.95M Buy
+540,000
New +$4.65M ﹤0.01% 1435

Other funds holding AH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JRP
Jasper Ridge Partners Menlo Park, California $4.49B AUM 18.72% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return

T. Rowe Price Associates's AH Position: Q1 2014 in Review

T. Rowe Price Associates sold out of Accretive Health (AH) in Q1 2014, closing a stake of 540,000 shares — an estimated $4.95M sold.

T. Rowe Price Associates first reported a position in AH in Q4 2013 and held it in 1 quarter. The position peaked at $4.95M in Q4 2013. 66 funds tracked by Wall St. Rank hold AH as of Q1 2014.

  • T. Rowe Price Associates reported no remaining Accretive Health position as of Q1 2014 after selling out during the quarter.
  • T. Rowe Price Associates sold 540,000 Accretive Health shares in Q1 2014, an estimated $4.95M.
  • T. Rowe Price Associates first reported a position in Accretive Health in Q4 2013 and held it in 1 quarter.
  • T. Rowe Price Associates's Accretive Health position peaked at $4.95M in Q4 2013.
  • 66 funds tracked by Wall St. Rank held Accretive Health as of Q1 2014.

Based on T. Rowe Price Associates's 13F filing for Q1 2014, filed 15 May 2014.